MARKHAM, ON, May 6, 2015 /CNW/ – Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma, Inc. (Tokyo: 4503), and the Canadian National Transplant Research Program (CNTRP), are pleased to announce the recipients of the first CNTRP Astellas research innovation grant competition.
In 2013, Astellas entered into a commitment with the transplant scientific community through a research partnership with the CNTRP. Astellas has pledged $1 Million over a period of five years to support Canadian investigators as they work to address barriers to tissue and organ donation and improve long-term outcomes and quality of life for transplant patients.
Last year, Astellas launched the 2014 CNTRP Astellas Research Innovation Grant Competition, committing an additional $50,000 to support peer-reviewed pilot research project(s) in the area of personalized medicine approaches in transplantation to improve long-term health outcomes.
Source: www.newswire.ca
The post Richmond Hill Based Astellas Pharma Canada Inc. and the CNTRP Partner to Support Personalized Medicine Approaches to Improve Transplantation appeared first on Invest in York - Toronto Area's Tech Hub.